Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?
- 27 May 2014
- journal article
- review article
- Published by Wiley in Journal of Internal Medicine
- Vol. 275 (6), 551-561
- https://doi.org/10.1111/joim.12159
Abstract
A growing number of international initiatives (e.g. EU-ADR, Sentinel, OMOP, PROTECT and VAESCO) are based on the combined use of multiple healthcare databases for the conduct of active surveillance studies in the area of drug and vaccine safety. The motivation behind combining multiple healthcare databases is the earlier detection and validation, and hence earlier management, of potential safety issues. Overall, the combination of multiple healthcare databases increases statistical sample size and heterogeneity of exposure for postmarketing drug and vaccine safety surveillance, despite posing several technical challenges. Healthcare databases generally differ by underlying healthcare systems, type of information collected, drug/vaccine and medical event coding systems and language. Therefore, harmonization of medical data extraction through homogeneous coding algorithms across highly different databases is necessary. Although no standard procedure is currently available to achieve this, several approaches have been developed in recent projects. Another main challenge involves choosing the work models for data management and analyses whilst respecting country-specific regulations in terms of data privacy and anonymization. Dedicated software (e.g. Jerboa) has been produced to deal with privacy issues by sharing only anonymized and aggregated data using a common data model. Finally, storage and safe access to the data from different databases requires the development of a proper remote research environment. The aim of this review is to provide a summary of the potential, disadvantages, methodological issues and possible solutions concerning the conduct of postmarketing multidatabase drug and vaccine safety studies, as demonstrated by several international initiatives.Keywords
This publication has 28 references indexed in Scilit:
- Active Surveillance of Postmarket Medical Product Safety in the Federal Partners' CollaborationMedical Care, 2012
- The Food and Drug Administration's Post‐Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprisePharmacoepidemiology and Drug Safety, 2012
- The New Sentinel Network — Improving the Evidence of Medical-Product SafetyThe New England Journal of Medicine, 2009
- Improving reporting of adverse drug reactions: Systematic reviewClinical Epidemiology, 2009
- Primer: administrative health databases in observational studies of drug effects—advantages and disadvantagesNature Clinical Practice Rheumatology, 2007
- Data mining for signals in spontaneous reporting databases: proceed with cautionPharmacoepidemiology and Drug Safety, 2006
- Use of Health Care Databases in PharmacoepidemiologyBasic & Clinical Pharmacology & Toxicology, 2006
- Use of the UK General Practice Research Database for pharmacoepidemiologyBritish Journal of Clinical Pharmacology, 1998
- Limitations and strengths of spontaneous reports dataClinical Therapeutics, 1998
- Vaccine Safety Datalink Project: A New Tool for Improving Vaccine Safety Monitoring in the United StatesPEDIATRICS, 1997